Antiretroviral therapy and preterm birth in HIV-infected women

References

• Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331(18):1173-80
   PubMed Web of Science ®Google Scholar
• Duong T, Ades AE, Gibb DM, et al. Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data. BMJ 1999;319(7219):1227-9
   PubMed Web of Science ®Google Scholar
• Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008;22(8):973-81
   PubMed Web of Science ®Google Scholar
• Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010;362(24):2282-94
   PubMed Web of Science ®Google Scholar
• Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372(9635):293-9
   PubMed Web of Science ®Google Scholar
• European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999;353(9158):1035-9
   PubMed Web of Science ®Google Scholar
• WHO. Consolidated guidelines of the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach. WHO; Geneva, Switzerland: 2013
   Google Scholar
• WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach. WHO; Geneva, Switzerland: 2010
   Google Scholar
• Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998;12(18):F241-7
   Web of Science ®Google Scholar
• Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005;38(4):449-73
   PubMed Web of Science ®Google Scholar
• Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002;78(1):58-9
   PubMed Web of Science ®Google Scholar
• Hernandez S, Moren C, Lopez M, et al. Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn. AIDS 2012;26(4):419-28
   PubMedGoogle Scholar
• Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004;36(3):772-6
   PubMed Web of Science ®Google Scholar
• El Beitune P, Duarte G, Foss MC, et al. Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women. Diabetes Metab Res Rev 2006;22(1):59-63
   PubMed Web of Science ®Google Scholar
• Watts DH, Balasubramanian R, Maupin RT Jr, et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 2004;190(2):506-16
   PubMedGoogle Scholar
• Marti C, Pena JM, Bates I, et al. Obstetric and perinatal complications in HIV-infected women. Analysis of a cohort of 167 pregnancies between 1997 and 2003. Acta Obstet Gynecol Scand 2007;86(4):409-15
   PubMed Web of Science ®Google Scholar
• Gonzalez-Tome MI, Ramos Amador JT, Guillen S, et al. Gestational diabetes mellitus in a cohort of HIV-1 infected women. HIV Med 2008;9(10):868-74
   PubMed Web of Science ®Google Scholar
• Livingston EG, Cohn SE, Yang Y, et al. Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy. Obstet Gynecol 2007;110(2 Pt 1):391-7
   PubMedGoogle Scholar
• Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002;360(9340):1152-4
   PubMed Web of Science ®Google Scholar
• Suy A, Martinez E, Coll O, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006;20(1):59-66
   PubMed Web of Science ®Google Scholar
• Darak S, Darak T, Kulkarni S, et al. Effect of highly active antiretroviral treatment (HAART) during pregnancy on pregnancy outcomes: experiences from a PMTCT program in western India. AIDS Patient Care STDS 2013;27(3):163-70
   PubMed Web of Science ®Google Scholar
• Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011;204(4):506-14
   PubMed Web of Science ®Google Scholar
• Baroncelli S, Tamburrini E, Ravizza M, et al. Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS 2009;23(7):513-20
   PubMedGoogle Scholar
• Parekh N, Ribaudo H, Souda S, et al. Risk factors for very preterm delivery and delivery of very-small-for-gestational-age infants among HIV-exposed and HIV-unexposed infants in Botswana. Int J Gynaecol Obstet 2011;115(1):20-5
   PubMed Web of Science ®Google Scholar
• Grosch-Woerner I, Puch K, Maier RF, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008;9(1):6-13
   PubMed Web of Science ®Google Scholar
• Ravizza M, Martinelli P, Bucceri A, et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 2007;195(6):913-14. author reply 916-17
   PubMedGoogle Scholar
• Schulte J, Dominguez K, Sukalac T, et al. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics 2007;119(4):e900-6
   PubMed Web of Science ®Google Scholar
• Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006;193(9):1195-201
   PubMed Web of Science ®Google Scholar
• Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007;21(5):607-15
   PubMed Web of Science ®Google Scholar
• Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis 2012;54(9):1348-60
   PubMed Web of Science ®Google Scholar
• Combination antiretroviral therapy and duration of pregnancy. AIDS 2000;14(18):2913-20
   PubMed Web of Science ®Google Scholar
• van der Merwe K, Hoffman R, Black V, et al. Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. J Int AIDS Soc 2011;14:42
   PubMed Web of Science ®Google Scholar
• Cecchini D, Uruena A, Trinidad P, et al. HIV and pregnancy: maternal and neonatal evolution. Medicina (B Aires) 2011;71(5):432-6
   PubMedGoogle Scholar
• Dryden-Peterson S, Shapiro RL, Hughes MD, et al. Increased risk of severe infant anemia following exposure to maternal hAART, Botswana. J Acquir Immune Defic Syndr 2011;56(5):428-36
   PubMedGoogle Scholar
• European Collaborative Study. Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1-infected mothers. AIDS 2004;18(15):2009-17
   PubMedGoogle Scholar
• Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354(9184):1084-9
   PubMed Web of Science ®Google Scholar
• Simon A, Warszawski J, Kariyawasam D, et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 2011;306(1):70-8
   PubMedGoogle Scholar
• Beck S, Wojdyla D, Say L, et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ 2010;88(1):31-8
   PubMed Web of Science ®Google Scholar
• Sukhov A, Wu Y, Xing G, et al. Risk factors associated with cerebral palsy in preterm infants. J Matern Fetal Neonatal Med 2012;25(1):53-7
   PubMedGoogle Scholar
• Tucker J, McGuire W. Epidemiology of preterm birth. BMJ 2004;329(7467):675-8
   PubMed Web of Science ®Google Scholar
• Talge NM, Holzman C, Wang J, et al. Late-preterm birth and its association with cognitive and socioemotional outcomes at 6 years of age. Pediatrics 2010;126(6):1124-31
   PubMed Web of Science ®Google Scholar
• Boyle EM, Poulsen G, Field DJ, et al. Effects of gestational age at birth on health outcomes at 3 and 5 years of age: population based cohort study. BMJ 2012;344:e896
   PubMed Web of Science ®Google Scholar
• Marchant T, Willey B, Katz J, et al. Neonatal mortality risk associated with preterm birth in East Africa, adjusted by weight for gestational age: individual participant level meta-analysis. PLoS Med 2012;9(8):e1001292
   Google Scholar
• Rudin C, Spaenhauer A, Keiser O, et al. Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data. HIV Med 2011;12(4):228-35
   PubMed Web of Science ®Google Scholar
• Boer K, Nellen JF, Patel D, et al. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. BJOG 2007;114(2):148-55
   PubMed Web of Science ®Google Scholar
• Aebi-Popp K, Lapaire O, Glass TR, et al. Pregnancy and delivery outcomes of HIV infected women in Switzerland 2003-2008. J Perinat Med 2010;38(4):353-8
   PubMedGoogle Scholar
• Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007;21(8):1019-26
   PubMed Web of Science ®Google Scholar
• Musana JW, Ojwang SB, Khisa W, Kiarie JN. Pregnancy outcomes in mothers with advanced human immunodeficiency virus disease. East Afr Med J 2009;86(10):480-5
   PubMedGoogle Scholar
• Turner AN, Tabbah S, Mwapasa V, et al. Severity of maternal HIV-1 disease is associated with adverse birth outcomes in malawian women: a Cohort Study. J Acquir Immune Defic Syndr 2013;64(4):392-9
   PubMedGoogle Scholar
• Traisathit P, Mary JY, Le Coeur S, et al. Risk factors of preterm delivery in HIV-infected pregnant women receiving zidovudine for the prevention of perinatal HIV. J Obstet Gynaecol Res 2009;35(2):225-33
   PubMedGoogle Scholar
• Azria E, Moutafoff C, Schmitz T, et al. Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen. Antivir Ther 2009;14(3):423-32
   PubMed Web of Science ®Google Scholar
• Liuzzi G, Pinnetti C, Floridia M, et al. Pregnancy outcomes in HIV-infected women of advanced maternal age. HIV Clin Trials 2013;14(3):110-19
   PubMed Web of Science ®Google Scholar
• Salihu HM, Mogos MF, August EM, et al. HIV infection and its impact on fetal outcomes among women of advanced maternal age: a propensity score weighted matching approach. AIDS Res Hum Retroviruses 2013;29(3):581-7
   PubMedGoogle Scholar
• Brown K, Holland B, Mosquera C, et al. Human immunodeficiency virus infection in advanced maternal age gravidas. AIDS Res Hum Retroviruses 2012;28(3):265-9
   PubMedGoogle Scholar
• Parikh L, Timofeev J, Singh J, et al. Racial Disparities in Maternal and Neonatal Outcomes in HIV-1 Positive Mothers. Am J Perinatol 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Olusanya BO, Ofovwe GE. Predictors of preterm births and low birthweight in an inner-city hospital in sub-Saharan Africa. Matern Child Health J 2010;14(6):978-86
   PubMed Web of Science ®Google Scholar
• Aliyu MH, Weldeselasse H, August EM, et al. Cigarette smoking and fetal morbidity outcomes in a large cohort of HIV-infected mothers. Nicotine Tob Res 2012;15(1):177-84
   PubMedGoogle Scholar
• Haeri S, Shauer M, Dale M, et al. Obstetric and newborn infant outcomes in human immunodeficiency virus-infected women who receive highly active antiretroviral therapy. Am J Obstet Gynecol 2009;201(3):315. e1-5
   PubMedGoogle Scholar
• Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012;206(11):1695-705
   PubMed Web of Science ®Google Scholar
• Lambert JS, Watts DH, Mofenson L, et al. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team. AIDS 2000;14(10):1389-99
   PubMedGoogle Scholar
• Morris AB, Cu-Uvin S, Harwell JI, et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr 2000;25(4):306-11
   Google Scholar
• Thorne C, Semenenko I, Malyuta R. Prevention of mother-to-child transmission of human immunodeficiency virus among pregnant women using injecting drugs in Ukraine, 2000-10. Addiction 2012;107(1):118-28
   PubMedGoogle Scholar
• Yu L, Li WY, Chen RY, et al. Pregnancy outcomes and risk factors for low birth weight and preterm delivery among HIV-infected pregnant women in Guangxi, China. Chin Med J 2012;125(3):403-9
   PubMed Web of Science ®Google Scholar
• Young S, Murray K, Mwesigwa J, et al. Maternal nutritional status predicts adverse birth outcomes among HIV-infected rural Ugandan women receiving combination antiretroviral therapy. PLoS One 2012;7(8):e41934
   Web of Science ®Google Scholar
• Andrews WW, Goldenberg RL, Hauth JC. Preterm labor: emerging role of genital tract infections. Infect Agents Dis 1995;4(4):196-211
   PubMedGoogle Scholar
• Goldenberg RL, Mudenda V, Read JS, et al. HPTN 024 study: histologic chorioamnionitis, antibiotics and adverse infant outcomes in a predominantly HIV-1-infected African population. Am J Obstet Gynecol 2006;195(4):1065-74
   PubMedGoogle Scholar
• Schuetz AN, Guarner J, Packard MM, et al. Infectious disease immunohistochemistry in placentas from HIV-positive and HIV-negative patients. Pediatr Dev Pathol 2011;14(3):180-8
   PubMedGoogle Scholar
• D'Costa G F, Khadke K, Patil YV. Pathology of placenta in HIV infection. Indian J Pathol Microbiol 2007;50(3):515-19
   PubMedGoogle Scholar
• Mania A, Kemnitz P, Cudnoch K, et al. Clinical condition and transmission of coinfections with human cytomegalovirus in infants of HIV-1 infected mothers in the era of mother-to-child-transmission prophylaxis. Early Hum Dev 2012;89(2):119-24
   PubMedGoogle Scholar
• Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004;18(17):2337-9
   PubMed Web of Science ®Google Scholar
• Lopez M, Figueras F, Hernandez S, et al. Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART. AIDS 2012;26(1):37-43
   PubMed Web of Science ®Google Scholar
• Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: a single-center cohort study. J Infect Dis 2007;196(4):558-61
   PubMed Web of Science ®Google Scholar
• Short CE, Douglas M, Smith J, Taylor G. Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission. HIV Med 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Bellon Cano JM, Sanchez-Ramon S, Ciria L, et al. The effects on infants of potent antiretroviral therapy during pregnancy: a report from Spain. Med Sci Monit 2004;10(5):CR179-84
   Google Scholar
• Kowalska A, Niemiec T, El Midaoui A, Burkacka E. Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women. Med Wieku Rozwoj 2003;7(4 Pt 1):459-68
   PubMedGoogle Scholar
• Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002;346(24):1863-70
   PubMed Web of Science ®Google Scholar
• Watts DH, Williams PL, Kacanek D, et al. Combination antiretroviral use and preterm birth. J Infect Dis 2013;207(4):612-21
   PubMed Web of Science ®Google Scholar
• Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 2006;20(18):2345-53
   PubMed Web of Science ®Google Scholar
• Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect 2009;85(2):82-7
   PubMed Web of Science ®Google Scholar
• Marazzi MC, Palombi L, Nielsen-Saines K, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS 2011;25(13):1611-18
   PubMed Web of Science ®Google Scholar
• Townsend C, Schulte J, Thorne C, et al. Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe. BJOG 2010;117(11):1399-410
   PubMed Web of Science ®Google Scholar
• de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011;11(3):171-80
   PubMed Web of Science ®Google Scholar
• Patel K, Shapiro DE, Brogly SB, et al. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis 2010;201(7):1035-44
   PubMed Web of Science ®Google Scholar
• Dola CP, Khan R, DeNicola N, et al. Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy. J Perinat Med 2011;40(1):51-5
   PubMedGoogle Scholar
• Powis KM, McElrath TF, Hughes MD, et al. High viral load and elevated angiogenic markers associated with increased risk of preeclampsia among women initiating highly active antiretroviral therapy in pregnancy in the Mma Bana study, Botswana. J Acquir Immune Defic Syndr 2013;62(5):517-24
   PubMed Web of Science ®Google Scholar
• Hunt JS. Stranger in a strange land. Immunol Rev 2006;213:36-47
   PubMed Web of Science ®Google Scholar
• Sykes L, MacIntyre DA, Yap XJ, et al. The Th1:th2 dichotomy of pregnancy and preterm labour. Mediators Inflamm 2012;2012:967629
   PubMed Web of Science ®Google Scholar
• Challis JR, Lockwood CJ, Myatt L, et al. Inflammation and pregnancy. Reprod Sci 2009;16(2):206-15
   PubMed Web of Science ®Google Scholar
• Klein SA, Dobmeyer JM, Dobmeyer TS, et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 1997;11(9):1111-18
   PubMedGoogle Scholar
• Clerici M, Seminari E, Maggiolo F, et al. Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients. AIDS 2002;16(13):1767-73
   PubMed Web of Science ®Google Scholar
• Barcellini W, Rizzardi GP, Borghi MO, et al. TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS 1994;8(6):757-62
   PubMedGoogle Scholar
• Fiore S, Newell ML, Trabattoni D, et al. Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol 2006;70(1-2):143-50
   PubMedGoogle Scholar
• Short C, Foster R, Douglas M, et al. Reduced interleukin-10 in pregnant women receiving protease inhibitor or NNRTI based ART compared to NRTI- only regimes -a potential contributor to pre-term delivery. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; 3 – 8 March 2012; Seattle, WA, USA
   Google Scholar
• NIH IMPAACT Protocol 1077BF: Breast Feeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere). Available from: https://impaactgroup.org/files/IMPAACT1077BFVersion3Dated15October2012withCM1.pdf [Last accessed 12th December 2013]
   Google Scholar
• Ekouevi DK, Inwoley A, Tonwe-Gold B, et al. Variation of CD4 count and percentage during pregnancy and after delivery: implications for HAART initiation in resource-limited settings. AIDS Res Hum Retroviruses 2007;23(12):1469-74
   PubMed Web of Science ®Google Scholar
• Ackerman IV W, Kwiek JJ. Role of the placenta in adverse perinatal outcomes among HIV-1 seropositive women. J Nippon Med Sch 2013;80(2):90-4
   PubMedGoogle Scholar
• Papp E, Loutfy M, Yudin M, et al. Angiogenesis and adverse pregnancy outcomes in women with HIV: The AAPH study. Presented at: 3rd International Conference on HIV and Women; 14 – 15 January 2013; Toronto, Canada
   Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350(7):672-83
   PubMed Web of Science ®Google Scholar
• Veas CJ, Aguilera VC, Munoz IJ, et al. Fetal endothelium dysfunction is associated with circulating maternal levels of sE-selectin, sVCAM1, and sFlt-1 during pre-eclampsia. J Matern Fetal Neonatal Med 2011;24(11):1371-7
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21(1):9-23
   PubMed Web of Science ®Google Scholar
• Johnson MR, Anim-Nyame N, Johnson P, et al. Does endothelial cell activation occur with intrauterine growth restriction? BJOG 2002;109(7):836-9
   PubMed Web of Science ®Google Scholar
• Krauss T, Emons G, Kuhn W, Augustin HG. Predictive value of routine circulating soluble endothelial cell adhesion molecule measurements during pregnancy. Clin Chem 2002;48(9):1418-25
   PubMedGoogle Scholar
• Short C, Foster R, Douglas M, et al. Elevated leukocyte adhesion marker VCAM-1 in HIV-1 infected in women initiating PI-based ART during pregnancy compared to women conceiving on PI-based ART and women initiating triple-NRTI ART. HIV Med 2013;14(S2):6
   PubMedGoogle Scholar
• Baurakiades E, Martins AP, Victor Moreschi N, et al. Histomorphometric and immunohistochemical analysis of infectious agents, T-cell subpopulations and inflammatory adhesion molecules in placentas from HIV-seropositive pregnant women. Diagn Pathol 2011;6:101
   PubMedGoogle Scholar
• McLean M, Bisits A, Davies J, et al. A placental clock controlling the length of human pregnancy. Nat Med 1995;1(5):460-3
   PubMed Web of Science ®Google Scholar
• Papp E, Serghides L. Progesterone level changes after cART exposure in vitro and in vivo are possibly linked to adverse birth outcomes. Presented at: 3rd International Workshop on HIV and Women; 14–15 January 2013; Toronto, Canada
   Google Scholar
• Senise JF, Castelo A, Martinez M. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. AIDS Rev 2011;13(4):198-213
   PubMed Web of Science ®Google Scholar
• Townsend CL, Willey BA, Cortina-Borja M, et al. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS 2009;23(4):519-24
   PubMedGoogle Scholar
• The Antiretroviral Pregnancy Registry. Interim Report; 2013
   Google Scholar
• Townsend CL, Tookey PA, Newell ML, Cortina-Borja M. Antiretroviral therapy in pregnancy: balancing the risk of preterm delivery with prevention of mother-to-child HIV transmission. Antivir Ther 2010;15(5):775-83
   PubMed Web of Science ®Google Scholar
• UNAIDS. Report on the global AIDS epidemic; 2013
   Google Scholar
• Watts DH, Lu M, Thompson B, et al. Treatment interruption after pregnancy: effects on disease progression and laboratory findings. Infect Dis Obstet Gynecol 2009;2009:456717
   PubMedGoogle Scholar
• Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5(10):e203
   PubMed Web of Science ®Google Scholar
• Coutsoudis A, Goga A, Desmond C, et al. Is Option B+ the best choice? Lancet 2013;381(9863):269-71.2013
   PubMedGoogle Scholar
• Aebi-Popp K, Mulcahy F, Glass T, et al. Vaginal delivery as option for HIV - positive women: decreasing late preterm delivery rates in a European cohort collaboration. Presented at: 5th International Workshop on HIV Pediatrics; 28 – 29 June 2013; Kuala Lumpur, Malasia
   Google Scholar
• Fang LW, Xing ZL, Wang LH, et al. [Influencing factors on the death of infants born to HIV infected mothers]. Zhonghua Yu Fang Yi Xue Za Zhi 2009;43(11):991-5
   PubMedGoogle Scholar
• Romero R, Nicolaides K, Conde-Agudelo A, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 2012;206(2):124. e121-119
   PubMedGoogle Scholar
• Di Renzo GC, Roura LC, Facchinetti F, et al. Guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth. J Matern Fetal Neonatal Med 2011;24(5):659-67
   PubMed Web of Science ®Google Scholar
• Lamont RF, Nhan-Chang CL, Sobel JD, et al. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 2011;205(3):177-90
   PubMed Web of Science ®Google Scholar
• Goldenberg R AW, Taha T, Fawzi W, Brown E. HIVNET 024: fetal fibronectin (FFN), preterm birth (PTB) and mother to child transmission of HIV (MTCT) in African women with HIV. Am J Obstet Gynecol 2005;193(6):S52
   Google Scholar